Related Experiment Videos
Molecular targets from VHL studies into the oxygen-sensing pathway
1Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada. michael.ohh@utoronto.ca
Current Cancer Drug Targets
|August 17, 2005
Summary
Von Hippel-Lindau (VHL) disease results from a faulty VHL tumor suppressor gene, leading to tumor development. Understanding the VHL-HIF pathway is crucial for developing targeted anti-cancer drugs.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Von Hippel-Lindau (VHL) disease is an inherited disorder causing tumors due to a faulty VHL tumor suppressor gene.
- The VHL gene product (pVHL) is essential for degrading hypoxia-inducible factor (HIF).
- Dysregulation of the VHL-HIF pathway is implicated in various cancers.
Purpose of the Study:
- To elucidate the role of the VHL gene and its product pVHL in tumor development.
- To understand the VHL-HIF pathway's significance in oxygen homeostasis and oncogenesis.
- To explore the potential of targeting the VHL-HIF pathway for novel cancer therapies.
Main Methods:
- Investigated the function of the VHL gene product pVHL within an E3 ubiquitin ligase complex.
- Analyzed the polyubiquitination and degradation of hypoxia-inducible factor (HIF) by pVHL.
- Examined the accumulation of HIF and downstream genes like VEGF in VHL-deficient tumor cells.
Main Results:
- Faulty VHL leads to pVHL deficiency, causing HIF accumulation.
- Elevated HIF drives the expression of angiogenic factors like VEGF, promoting tumor growth.
- HIF is frequently elevated in human cancers, highlighting its oncogenic role.
Conclusions:
- Disruptions in the VHL-HIF oxygen-sensing pathway contribute to tumorigenesis.
- VHL disease serves as a model for studying targeted therapies against the VHL-HIF pathway.
- Targeting the VHL-HIF pathway offers a promising strategy for next-generation anti-cancer drugs.